var data={"title":"Amoxicillin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amoxicillin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5631?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">see &quot;Amoxicillin: Drug information&quot;</a> and <a href=\"topic.htm?path=amoxicillin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amoxicillin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134511\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Moxatag</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134512\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Novamoxin;</li>\n      <li>Pro-Amox-250;</li>\n      <li>Pro-Amox-500</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045040\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Penicillin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11431486\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> All neonatal dosing recommendations based on immediate release product formulations (ie, oral suspension).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b> Oral: 20 to 30 mg/kg/day in divided doses every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otitis media, acute (AOM), Group A or B streptococcus:</b> Oral stepdown therapy after IV/IM penicillin or ampicillin: Oral: 30 to 40 mg/kg/day in divided doses every 8 hours (Bradley 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>UTI, prophylaxis (hydronephrosis, vesicoureteral reflux):</b> Oral: 10 to 15 mg/kg once daily (Belarmino 2006; Greenbaum 2006; Mattoo 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045033\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">see &quot;Amoxicillin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Unless otherwise specified, all pediatric dosing recommendations based on immediate release product formulations (oral suspension, chewable tablet, tablet, and capsule).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &le;3 months: Oral: 25 to 50 mg/kg/day in divided doses every 8 hours (<i>Red Book</i> [AAP 2015]). <b>Note:</b> Manufacturer's labeling recommends a maximum daily dose of 30 mg/kg/<b>day</b> divided into 2 doses per day for this age group.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &gt;3 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AAP recommendations (<i>Red Book</i> [AAP 2015]): Oral: 25 to 50 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: Oral: 20 to 40 mg/kg/day in divided doses every 8 hours (maximum dose: 500 mg/dose) <b>or</b> 25 to 45 mg/kg/day in divided doses every 12 hours (maximum dose: 875 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection (as step-down therapy): Infants, Children, and Adolescents: Oral: 80 to 100 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg/dose for most indications (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anthrax:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cutaneous, without systemic involvement: Infants, Children, and Adolescents: Oral: 75 mg/kg/day in 3 divided doses. Maximum dose: 1,000 mg/dose. Duration of therapy: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related exposure (AAP [Bradley 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalational, postexposure prophylaxis: Infants, Children, and Adolescents: Oral: 75 mg/kg/day in divided doses every 8 hours for 60 days after exposure; maximum dose: 1,000 mg/dose (AAP [Bradley 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis), exit-site or tunnel infection:</b> Infants, Children, and Adolescents: Oral: 10 to 20 mg/kg once daily; maximum dose: 1,000 mg/dose (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, prophylaxis:</b> <b>Note: </b>AHA guidelines (Baltimore 2015) limit the use of prophylactic antibiotics to patients at the highest risk for infective endocarditis (IE) or adverse outcomes (eg, prosthetic heart valves, patients with previous IE, unrepaired cyanotic congenital heart disease, repaired congenital heart disease with prosthetic material or device during first 6 months after procedure, repaired congenital heart disease with residual defects at the site or adjacent to site of prosthetic patch or device, heart transplant recipients with cardiac valvulopathy):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dental or oral procedures or respiratory tract procedures (eg, tonsillectomy, adenoidectomy):</i> Infants, Children, and Adolescents: Oral: 50 mg/kg 30 to 60 minutes before procedure; maximum dose: 2,000 mg/dose (AHA [Wilson 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>H. pylori</i> eradication:</b> Children and Adolescents: Oral: 50 mg/kg/day in 2 divided doses for 10 to 14 days. <b>Note:</b> Duration dependent on regimen used; maximum daily dose: 2,000 mg/<b>day</b>. Administer in combination with a proton pump inhibitor or bismuth subsalicylate and at least one other antibiotic (clarithromycin and/or metronidazole) (NASPGHAN/ESPGHAN [Koletzko 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme disease:</b> Infants, Children, and Adolescents: Oral: 50 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg/dose (Halperin 2007; IDSA [Wormser 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute (AOM):</b> Infants &ge;2 months and Children: Oral: 80 to 90 mg/kg/day in divided doses every 12 hours; variable duration of therapy, if &lt;2 years of age or severe symptoms (any age): 10-day course; if 2 to 5 years of age with mild to moderate symptoms: 7-day course; &ge;6 years of age with mild to moderate symptoms: 5- to 7-day course; some experts recommend initiating with 90 mg/kg/day (AAP [Lieberthal 2013]; <i>Red Book</i> [AAP 2015]); a maximum dose is not provided in the Guidelines for The Diagnosis and Management of Acute Otitis Media (AAP [Lieberthal 2013]); however, some experts suggest a maximum daily dose of 4,000 mg/<b>day</b> for high-dose amoxicillin therapy (Bradley 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis), prophylaxis for patients requiring invasive dental procedures:</b> Infants, Children, and Adolescents: Oral: 50 mg/kg administered 30 to 60 minutes before dental procedure; maximum dose: 2,000 mg/dose (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired:</b> Infants &ge; 3 months, Children, and Adolescents (IDSA [Bradley 2011]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Empiric therapy for presumed bacterial pneumonia: Oral: 90 mg/kg/day in divided doses every 12 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Group A <i>Streptococcus, </i>mild infection or step-down therapy: Oral: 50 to 75 mg/kg/day in divided doses every 12 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Haemophilus influenzae, </i>mild infection or step-down therapy: Oral: 75 to 100 mg/kg/day in divided doses every 8 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Streptococcus pneumonia</i> (penicillin MIC &le;2 mcg/mL); mild infection or step-down therapy: Oral: 90 mg/kg/day in divided doses every 12 hours <b>or</b> 45 mg/kg/day in divided doses every 8 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumococcal infection prophylaxis for anatomic or functional asplenia [eg, sickle cell disease (SCD)]</b> (Price 2007; <i>Red Book</i> [AAP 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Before 2 months of age (or as soon as SCD is diagnosed or asplenia occurs) through 5 years of age: Oral: 20 mg/kg/day in divided doses every 12 hours; maximum dose: 250 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years and Adolescents: Oral: 250 mg every 12 hours; <b>Note:</b> The decision to discontinue penicillin prophylaxis after 5 years of age in children who have not experienced invasive pneumococcal infection and have received recommended pneumococcal immunizations is patient and clinician dependent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinosinusitis, acute bacterial; uncomplicated:</b> <b>Note:</b> AAP guidelines recommend amoxicillin as first-line empiric therapy for pediatric patients 1 to 18 years with uncomplicated cases and where resistance is not suspected; however, the IDSA guidelines consider amoxicillin/clavulanate as the preferred therapy (IDSA [Chow 2012]; AAP [Wald 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low dose: Children &ge;2 years and Adolescents: Oral: 45 mg/kg/day in divided doses every 12 hours; <b>Note: </b>Only use for uncomplicated, mild to moderate infections in children who do not attend daycare and who have not received antibiotics within the last month (AAP [Wald 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High dose (use reserved for select patients; see <b>Note</b>): Children &ge;2 years and Adolescents: Oral: 80 to 90 mg/kg/day in divided doses every 12 hours; maximum dose: 2,000 mg/dose; <b>Note:</b> Should only use for mild to moderate infections in children who do not attend daycare and who have not received antibiotics within the last month and live in communities with a high prevalence of nonsusceptible <i>S. pneumoniae</i> resistance (AAP [Wald 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tonsillopharyngitis; Group A streptococcal infection, treatment and primary prevention of rheumatic fever:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (oral suspension, chewable tablets, tablets, capsules): Children and Adolescents 3 to 18 years: Oral: 50 mg/kg once daily <b>or</b> 25 mg/kg twice daily for 10 days; maximum daily dose: 1,000 mg/<b>day</b> (AHA [Gerber 2009]; IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release tablets: Children &ge;12 years and Adolescents: Oral: 775 mg once daily for 10 days; <b>Note:</b> Patient must be able to swallow tablet whole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>UTI, prophylaxis (hydronephrosis, vesicoureteral reflux):</b> Infants &le;2 months: Oral: 10 to 15 mg/kg once daily; some suggest administration in the evening (drug resides in bladder longer); <b>Note:</b> Due to resistance, amoxicillin should not be used for prophylaxis after 2 months of age (Belarmino 2006; Greenbaum 2006; Mattoo 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Oral: 250 to 500 mg every 8 hours <b>or</b> 500 to 875 mg tablets twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release tablet: Oral: 775 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chlamydial infection during pregnancy:</b> Oral: Immediate release: 500 mg 3 times daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lower respiratory tract infections:</b> Oral: Immediate release: 875 mg every 12 hours <b>or</b> 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tonsillitis and/or pharyngitis:</b> Oral: Extended release tablets: 775 mg once daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff 2007): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate infection: Dosing based on 25 to 50 mg/kg/day divided every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 8 to 20 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 8 to 20 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 8 to 20 mg/kg/dose every 24 hours; give after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Peritoneal dialysis: 8 to 20 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe infection (high dose): Dosing based on 80 to 90 mg/kg/day divided every 12 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 20 mg/kg/dose every 12 hours; do not use the 875 mg tablet</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 20 mg/kg/dose every 24 hours; do not use the 875 mg tablet</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 20 mg/kg/dose every 24 hours; give after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Peritoneal dialysis: 20 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Children &ge;12 years and Adolescents: CrCl &lt;30 mL/minute: Not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: <b>Note:</b> The immediate release 875 mg tablet should not be used in patients with a GFR &lt;30 mL/minute. Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;30 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 30 mL/minute: 250 to 500 mg every 12 hours depending on severity of infection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute: 250 to 500 mg every 24 hours depending on severity of infection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 250 to 500 mg every 24 hours; administer after dialysis on dialysis days (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: Not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134488\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (80 mL, 100 mL, 150 mL); 200 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (80 mL, 100 mL, 150 mL); 400 mg/5 mL (50 mL, 75 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 875 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moxatag: 775 mg [contains cremophor el, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 775 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134472\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045044\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: May be administered on an empty or full stomach; may be mixed with formula, milk, cold drink, or juice; administer dose immediately after mixing; shake suspension well before use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Take within 1 hour of finishing a meal; do not chew or crush tablet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134506\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Store at room temperature. Reconstituted oral suspension remains stable for 14 days at room temperature or refrigerated (refrigeration preferred). Unit-dose antibiotic oral syringes are stable at room temperature for at least 72 hours (Tu 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045043\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release preparations (oral suspension, chewable tablets, tablets, and capsules): Treatment of infections of ear, nose, skin, and soft tissue; genitourinary tract; or upper or lower respiratory tract due to susceptible (beta-lactamase negative) organisms (FDA approved in all ages); combination therapy of <i>Helicobacter pylori</i> (FDA approved in adults); has also been used for the treatment of Lyme disease, prophylaxis of bacterial endocarditis, prophylaxis in sickle cell or asplenic patients, prophylaxis of peritonitis in patients undergoing dental treatment or treatment of exit-site or tunnel infections in patients with peritoneal dialysis catheters, urinary tract infection prophylaxis, and postexposure prophylaxis and treatment of anthrax </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet (Moxatag): Treatment of tonsillitis and/or pharyngitis secondary to <i>Streptococcus pyogenes</i> (FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although FDA approved for the treatment of acute uncomplicated anogenital and urethral gonorrhea in men and women, clinical practice guidelines do not recommend amoxicillin for treatment of gonorrhea due to resistance (CDC [Workowski 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134569\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Amoxicillin may be confused with amoxapine, Augmentin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Amoxil may be confused with amoxapine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fisamox [Australia] may be confused with Fosamax brand name for alendronate [US, Canada, and multiple international markets] and Vigamox brand name for moxifloxacin [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Limoxin [Mexico] may be confused with Lanoxin brand name for digoxin [US, Canada, and multiple international markets]; Lincocin brand name for lincomycin [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zimox: Brand name for amoxicillin [Italy], but also the brand name for carbidopa/levodopa [Greece]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zimox [Italy] may be confused with Diamox which is the brand name for acetazolamide [Canada and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134567\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypersensitivity angiitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, anxiety, behavioral changes, confusion, dizziness, headache, hyperactivity (reversible), insomnia, seizure </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Acute generalized exanthematous pustulosis, erythematous maculopapular rash, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Dental discoloration (brown, yellow, or gray; rare), diarrhea, hemorrhagic colitis, melanoglossia, mucocutaneous candidiasis, nausea, pseudomembranous colitis, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Crystalluria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, eosinophilia, hemolytic anemia, leukopenia,thrombocytopenia, thrombocytopenia purpura </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic hepatitis, cholestatic jaundice, hepatitis (acute cytolytic), increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Serum sickness-like reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134495\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious hypersensitivity to amoxicillin (eg, anaphylaxis, Stevens-Johnson syndrome) or to other beta-lactams, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Infectious mononucleosis (suspected or confirmed)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134476\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, including amoxicillin, especially with a history of beta-lactam hypersensitivity (including severe reactions with cephalosporins) and/or a history of sensitivity to multiple allergens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis develop an erythematous rash during amoxicillin therapy; avoid use in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended in patients with GFR &lt;30 mL/minute. Avoid extended release 775 mg tablet and immediate release 875 mg tablet in patients with GFR &lt;30 mL/minute or patients requiring hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chewable tablets: May contain phenylalanine; see manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819741\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">Epstein-Barr virus infection (infectious mononucleosis), acute lymphocytic leukemia, or cytomegalovirus infection increases risk for amoxicillin-induced maculopapular rash. Appearance of a rash should be carefully evaluated to differentiate a nonallergic amoxicillin rash from a hypersensitivity reaction. Amoxicillin rash occurs in 5% to 10% of children receiving amoxicillin and is a generalized dull, red, maculopapular rash, generally appearing 3 to 14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees. A high percentage (43% to 100%) of patients with infectious mononucleosis have developed rash during therapy; amoxicillin-class antibiotics are not recommended in these patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298741\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134481\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12631&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134484\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5720643\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Amoxicillin crosses the placenta (Muller 2009). Maternal use of amoxicillin has generally not resulted in an increased risk of adverse fetal effects; however, a possible association with cleft lip with cleft palate has been observed in some studies (more data is needed) (Lin 2012; Puh&oacute; 2007). Amoxicillin may be used for the management of <i>Bacillus anthracis </i>in pregnant women when penicillin susceptibility is documented (Meaney-Delman 2014). Amoxicillin is an alternative antibiotic for the treatment of chlamydial infections in pregnancy (CDC [Workowski 2015]). Amoxicillin can also be used in the management of preterm premature rupture of membranes and in certain situations prior to vaginal delivery in women at high risk for endocarditis (ACOG 120 2011; ACOG 139 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of amoxicillin may be altered (Andrew 2007). Oral ampicillin-class antibiotics are poorly absorbed during labor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045039\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; observe for change in bowel frequency; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134475\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134494\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Immediate-release: Rapid with or without food</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release: Rate of absorption is slower compared to immediate-release formulations; food decreases the rate but not extent of absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Readily into liver, lungs, prostate, muscle, middle ear effusions, maxillary sinus secretions, bone, gallbladder, bile, and into ascitic and synovial fluids; poor CSF penetration (except when meninges are inflamed)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Adults: Immediate-release: 61.3 minutes; Extended-release: 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Capsule, oral suspension: 1 to 2 hours; Chewable tablet: 1 hour; Extended-release: 3.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (60% as unchanged drug) lower in neonates</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134497\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Amoxicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $24.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (500): $190.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Amoxicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $33.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $67.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Amoxicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (100 mL): $3.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (75 mL): $6.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (100 mL): $6.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/5 mL (75 mL): $7.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Moxatag Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">775 mg (10): $188.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amoxicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $49.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">875 mg (100): $87.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134499\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A.M. Mox (TH);</li>\n      <li>Abiolex (CL);</li>\n      <li>Acilina (PY);</li>\n      <li>Acimox (MX);</li>\n      <li>Adbiotin (CO);</li>\n      <li>Alfamox (IT);</li>\n      <li>Almacin (HR);</li>\n      <li>Almorsan (AR);</li>\n      <li>Alphamox (AU);</li>\n      <li>Amicil (MX);</li>\n      <li>Amimox (SE);</li>\n      <li>Amitron (ES);</li>\n      <li>Amixen (AR);</li>\n      <li>Amixozan (DK);</li>\n      <li>Ammimox (TH);</li>\n      <li>Amobay (MX);</li>\n      <li>Amobiotic (CL);</li>\n      <li>Amoclan (JO, SA);</li>\n      <li>Amodex (FR);</li>\n      <li>Amoksilav (TR);</li>\n      <li>Amoksyl (UA);</li>\n      <li>Amolin (JP);</li>\n      <li>Amorion (FI);</li>\n      <li>Amosin (RU);</li>\n      <li>Amotaks (PL);</li>\n      <li>Amoval (PE, PY);</li>\n      <li>Amox (IT);</li>\n      <li>Amoxa (SG);</li>\n      <li>Amoxal (CO, VE);</li>\n      <li>Amoxapen (ET, HK, MT);</li>\n      <li>Amoxar (DK);</li>\n      <li>Amoxcillin (TH);</li>\n      <li>Amoxen (ZW);</li>\n      <li>Amoxi-SAAR (DE);</li>\n      <li>Amoxibay (CO);</li>\n      <li>Amoxibel (JO);</li>\n      <li>Amoxibeta (DE);</li>\n      <li>Amoxicap (HK, PK, ZA);</li>\n      <li>Amoxicilina (CO, EC);</li>\n      <li>Amoxiclin (PE);</li>\n      <li>Amoxidal (AR, UY);</li>\n      <li>Amoxidin (AE);</li>\n      <li>Amoxidin 7 (PE);</li>\n      <li>Amoxidrex (LB);</li>\n      <li>Amoxifur (MX);</li>\n      <li>Amoxiga (CO, VE);</li>\n      <li>Amoxigran (HK);</li>\n      <li>Amoxil (AE, AU, BR, EC, EG, ET, GB, GR, ID, IE, JO, KW, LB, LT, MT, MX, NZ, PE, PT, QA, SA, ZA);</li>\n      <li>Amoxilan (AT, VE);</li>\n      <li>Amoxilin (CN);</li>\n      <li>Amoximex (LB);</li>\n      <li>Amoxin (FI, IS);</li>\n      <li>Amoxipen (AE, PE, VN);</li>\n      <li>Amoxipenil (CL);</li>\n      <li>Amoxisol (MX);</li>\n      <li>Amoxistad (AT);</li>\n      <li>Amoxitab (HK);</li>\n      <li>Amoxivan (IN);</li>\n      <li>Amoxivet (MX);</li>\n      <li>Amoxsan (ID);</li>\n      <li>Amoxy (CN);</li>\n      <li>Amoxy Care (IL);</li>\n      <li>Amoxydar (AE, JO, QA, SA);</li>\n      <li>Amoxypen (BE);</li>\n      <li>Ampin (PK);</li>\n      <li>Amyn (LK);</li>\n      <li>Anamox (PY);</li>\n      <li>Apimox (BD);</li>\n      <li>Aproxal (GR, JO);</li>\n      <li>Aroxin (SG);</li>\n      <li>Atak (BR);</li>\n      <li>Atoksilin (TR);</li>\n      <li>Avlomox (BD);</li>\n      <li>Bactimed (BE);</li>\n      <li>Bactox (LV);</li>\n      <li>Bactox Ge (FR);</li>\n      <li>Balmox (ZW);</li>\n      <li>Beamoxy (MY);</li>\n      <li>Betamox (MY);</li>\n      <li>Betmox (IN);</li>\n      <li>Brumox (PH);</li>\n      <li>Bufamoxy (ID);</li>\n      <li>Cilamox (AU);</li>\n      <li>Cipamox (PK, PT);</li>\n      <li>Clamoxyl (BE, CH, ES, FR, LU, PT);</li>\n      <li>Clonamox (HU, IE);</li>\n      <li>Coamox (TH);</li>\n      <li>Danoxilin (ID);</li>\n      <li>Devamox (TR);</li>\n      <li>Dimopen (MX);</li>\n      <li>Duomox (BG, CZ, HU, PL, RO);</li>\n      <li>Duzimicin (BR);</li>\n      <li>Dymoxin (TH);</li>\n      <li>E-Mox (AE, ET, QA, SA);</li>\n      <li>Ecobol (RU);</li>\n      <li>Edamox (HK);</li>\n      <li>Elmox (PK);</li>\n      <li>Ethimox (ID);</li>\n      <li>Fabamox (PY, UY);</li>\n      <li>Farconcil (EG);</li>\n      <li>Fisamox (AU);</li>\n      <li>Flemoksyn (UA);</li>\n      <li>Flemoxin (AE, BE, DK, EG, KW, NL, PT, QA, RU);</li>\n      <li>Foxolin (KR);</li>\n      <li>Geramox (IE);</li>\n      <li>Gexcil (PH);</li>\n      <li>Gimalxina (MX);</li>\n      <li>Glomox (AE, LB, QA, SA);</li>\n      <li>Gramox (RU);</li>\n      <li>Grinsul (AR);</li>\n      <li>Grunamox (EC);</li>\n      <li>Hiconcil (LT, LV, PL, VN);</li>\n      <li>Hikontsyl (UA);</li>\n      <li>Hymox (AE, JO, KW, QA, SA);</li>\n      <li>Hypher (CN);</li>\n      <li>Ibiamox (EG, NZ, TH);</li>\n      <li>Ikamoxyl (ID);</li>\n      <li>Imacillin (DK, NO, SE);</li>\n      <li>Imadrax (DK);</li>\n      <li>Imox (ET, ZW);</li>\n      <li>InfectoMox (DE);</li>\n      <li>J Mox (BD);</li>\n      <li>Julphamox (AE, JO, KW, LB, QA, SA);</li>\n      <li>Jutamox (DE);</li>\n      <li>Kemox (IN);</li>\n      <li>Kymoxin (KR);</li>\n      <li>Lamoxy (IN);</li>\n      <li>Largopen (ET);</li>\n      <li>Linmox (VE);</li>\n      <li>Loxyl (BD);</li>\n      <li>Magnimox (PE);</li>\n      <li>Manmox (TH);</li>\n      <li>Max (IN);</li>\n      <li>Maxamox (AU);</li>\n      <li>Medomox (ZW);</li>\n      <li>Meixil (TH);</li>\n      <li>Mexylin (ID);</li>\n      <li>Miloxy (ZW);</li>\n      <li>Mopen (IT);</li>\n      <li>Morgenxil (ES);</li>\n      <li>Mox (IN);</li>\n      <li>Moxatid (BD);</li>\n      <li>Moxi (LK);</li>\n      <li>Moxicor (LK);</li>\n      <li>Moxifar (UY);</li>\n      <li>Moxilen (HK, JO, LB, LV, MT, MY, RO, SG, VN);</li>\n      <li>Moxilin (BD);</li>\n      <li>Moxiram (JO);</li>\n      <li>Moxol (LK);</li>\n      <li>Moxtam (UY);</li>\n      <li>Moxxo (TH);</li>\n      <li>Moxylin (EC);</li>\n      <li>Moxypen (IL, ZA);</li>\n      <li>Moxyvit (IL);</li>\n      <li>Mymox (LV);</li>\n      <li>Neomox (AE, KW, SA);</li>\n      <li>Nobactam (AR);</li>\n      <li>Novamox (CL);</li>\n      <li>Novamoxin (KW);</li>\n      <li>Novax (ID);</li>\n      <li>Numoxylin (LK);</li>\n      <li>Ocylin (BR);</li>\n      <li>Opimox (ID);</li>\n      <li>Opimox Forte (ID);</li>\n      <li>Optamox (CL);</li>\n      <li>Oramox (IE);</li>\n      <li>Ospamoks (UA);</li>\n      <li>Ospamox (AE, AT, BG, CZ, EE, EG, HR, HU, ID, JO, KW, LB, LT, LV, MY, NZ, PL, PT, QA, RU, SA, SI, SK, VE);</li>\n      <li>Pamocil (IT, MT);</li>\n      <li>Pamoxin (KR);</li>\n      <li>Pasetocin (JP);</li>\n      <li>Penamox (AE, ET, JO, KW, LB, QA, SA);</li>\n      <li>Penbiosyn (PH);</li>\n      <li>Pinamox (IE);</li>\n      <li>Pondnoxcill (TH);</li>\n      <li>Pyramox (TH);</li>\n      <li>Ranmoxy (AU, NZ, ZA);</li>\n      <li>Ranoxyl (AE, TH, ZW);</li>\n      <li>Remox (SA);</li>\n      <li>Remoxil (TR);</li>\n      <li>Ri Ao (CN);</li>\n      <li>Rivamox (ET);</li>\n      <li>Sanet (PY);</li>\n      <li>Sapox (BD);</li>\n      <li>Sawacillin (JP);</li>\n      <li>Sia-mox (TH);</li>\n      <li>Sinot (UY);</li>\n      <li>Sintopen (IT);</li>\n      <li>Solpenox (ID);</li>\n      <li>Strimox (SG, ZW);</li>\n      <li>Taimox (PH);</li>\n      <li>Telmox (AR);</li>\n      <li>Teramoxyl (PH);</li>\n      <li>Trifamox (AR);</li>\n      <li>Trimoxal (VE);</li>\n      <li>Ultramox (JO, KW);</li>\n      <li>Unimox (SG);</li>\n      <li>Velamox (BR, PE);</li>\n      <li>Widecillin (ID, JP);</li>\n      <li>Winpen (LV);</li>\n      <li>Yomax (ZA);</li>\n      <li>Zai Lin (CN);</li>\n      <li>Zeemox (PK);</li>\n      <li>Zerrsox (PH);</li>\n      <li>Zimox (IT);</li>\n      <li>Zymoxyl (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol.</i> 2011;117(6):1472-1483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andrew MA, Easterling TR, Carr DB, et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. <i>Clin Pharmacol Ther.</i> 2007;81(4):547-556.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/17329990/pubmed\" target=\"_blank\" id=\"17329990\">17329990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belarmino JM and Kogan BA, &quot;Management of Neonatal Hydronephrosis,&quot; <i>Early Hum Dev</i>, 2006, 82(1):9-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/16427220/pubmed\" target=\"_blank\" id=\"16427220\">16427220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benyamini L, Merlob P, Stahl B, et al, &quot;The Safety of Amoxicillin/Clavulanic Acid and Cefuroxime During Lactation,&quot; <i>Ther Drug Monit</i>, 2005, 27(4):499-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/16044108/pubmed\" target=\"_blank\" id=\"16044108\">16044108</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boguniewicz M and Leung DY, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(3):221-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/7761188/pubmed\" target=\"_blank\" id=\"7761188\">7761188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 21st ed. American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-1436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/24777226 /pubmed\" target=\"_blank\" id=\"24777226 \">24777226 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canafax DM, Yuan Z, Chonmaitree T, et al, &ldquo;Amoxicillin Middle Ear Fluid Penetration and Pharmacokinetics in Children with Acute Otitis Media,&rdquo; <i>Pediatr Infect Dis J</i>, 1998, 17(2):149-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/9493813 /pubmed\" target=\"_blank\" id=\"9493813 \">9493813 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CDC and Johns Hopkins Working Group on Civilian Biodefense, &ldquo;Commentary on Non-Labeled Dosing of Oral Amoxicillin in Adults and Pediatrics for Post-Exposure Inhalational Anthrax,&rdquo; December 10, 2001, http://www.fda.gov/cder/drugprepare/amox-anthrax.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerber MA, Baltimore RS, Eaton CB, et al, &quot;Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute <i>Streptococcal pharyngitis</i>: A Scientific Statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,&quot; <i>Circulation</i>, 2009, 119(11):1541-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/19246689/pubmed\" target=\"_blank\" id=\"19246689\">19246689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M. The safety of macrolides during lactation. <i>Breastfeed Med</i>. 2009;4(4):197-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/19366316/pubmed\" target=\"_blank\" id=\"19366316\">19366316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenbaum LA and Mesrobian HG, &quot;Vesicoureteral Reflux,&quot; <i>Pediatr Clin North Am</i>, 2006 , 53(3):413-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/16716788/pubmed\" target=\"_blank\" id=\"16716788\">16716788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin JJ, Shapiro ED, Logigian E, et al, &quot;Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology,&quot; <i>Neurology</i>, 2007, 69(1):91-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/17522387/pubmed\" target=\"_blank\" id=\"17522387\">17522387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, et al, &quot;Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication,&quot; <i>Am J Obstet Gynecol</i>, 1993, 168(5):1393-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. <i>Acta Paediatr Scand.</i> 1981;70(3):285-288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/7246123/pubmed\" target=\"_blank\" id=\"7246123\">7246123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> infection in children. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(2):230-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/21558964 /pubmed\" target=\"_blank\" id=\"21558964 \">21558964 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al, &quot;The Diagnosis and Management of Acute Otitis Media,&quot; <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin KJ, Mitchell AA, Yau WP, Louik C, Hernandez-Diaz S. Maternal exposure to amoxicillin and the risk of oral clefts. <i>Epidemiology.</i> 2012;23(5):699-705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/22766750/pubmed\" target=\"_blank\" id=\"22766750\">22766750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mattoo TK, &quot;Medical Management of Vesicoureteral Reflux - Quiz Within the Article. Don't Overlook Placebos,&quot; <i>Pediatr Nephrol</i>, 2007, 22(8):1113-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/17483966/pubmed\" target=\"_blank\" id=\"17483966\">17483966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McIntosh K, &quot;Community-Acquired Pneumonia in Children,&quot; <i>N Engl J Med</i>, 2002, 346(6):429-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/11832532/pubmed\" target=\"_blank\" id=\"11832532\">11832532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/24457117/pubmed\" target=\"_blank\" id=\"24457117\">24457117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muller AE, Oostvogel PM, DeJongh J, et al. Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera. <i>Antimicrob Agents Chemother.</i> 2009;53(4):1574-1580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/19164154/pubmed\" target=\"_blank\" id=\"19164154\">19164154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of infections in children with asplenia or hyposplenia. <i>Infect Dis Clin North Am</i>. 2007;21(3):697-710.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/17826619/pubmed\" target=\"_blank\" id=\"17826619\">17826619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Puh&oacute; EH, Szunyogh M, M&eacute;tneki J, Czeizel AE. Drug treatment during pregnancy and isolated orofacial clefts in hungary. <i>Cleft Palate Craniofac J.</i> 2007;44(2):194-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/17328645/pubmed\" target=\"_blank\" id=\"17328645\">17328645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &quot;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&quot; Clin Infect Dis, 2012. Available at http://aapredbook.aappublications.org/cgi/content/full 22965026</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tu YH, Stiles ML, Allen LV Jr, et al. Stability of amoxicillin trihydrate-potassium clavulanate in original containers and unit dose oral syringes. <i>Am J Hosp Pharm</i>. 1988;45(5):1092-1099.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/3400652/pubmed\" target=\"_blank\" id=\"3400652\">3400652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1-18 years. <i>Pediatrics</i>. 2013;132:e262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/23796742/pubmed\" target=\"_blank\" id=\"23796742\">23796742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, 32(Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &quot;Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&quot; <i>Circulation</i>, 2007, 116(15):1736-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &quot;Mastitis: Causes and Management, Publication Number WHO/FCH/CAH/00.13,&quot; World Health Organization: Geneva, 2000.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-pediatric-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12631 Version 235.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F134511\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134512\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045040\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11431486\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045033\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134488\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F134472\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045044\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F134506\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045043\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134569\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134567\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134495\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134476\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819741\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298741\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134481\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134484\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5720643\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045039\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134475\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F134494\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F134497\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F134499\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12631|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">Amoxicillin: Drug information</a></li><li><a href=\"topic.htm?path=amoxicillin-patient-drug-information\" class=\"drug drug_patient\">Amoxicillin: Patient drug information</a></li></ul></div></div>","javascript":null}